PARP inhibitors can not only prolong the prognosis of ovarian cancer patients with genetic mutation (BRCA 1/2 mutation or HRD mutation), but also prolong the prognosis of ovarian cancer patients of no gene mutation. This evidence concerns the gene PARP1 and ovarian carcinoma.